Search Within

Gary Schwartz

  1. "Biostatistics Service"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (31)
Groups
  1. Biostatistics Service (68)
  2. Epidemiology and Biostatistics (68)
  3. Department of Medicine (58)
  4. Solid Tumor Oncology Division (57)
  5. Center for Pancreatic Cancer Research (30)
  6. GSK Faculty (28)

More Groups

People
  1. Richard Carvajal (30)
  2. Mithat Gonen (22)
  3. Manish Shah (21)
  4. Li-Xuan Qin (19)
  5. Mark Dickson (19)
  6. David Kelsen (17)

More People

Years
  1. 2016 (1)
  2. 2015 (1)
  3. 2014 (5)
  4. 2013 (14)
  5. 2012 (8)
  6. 2011 (5)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Clinical Cancer Research (13)
  3. Cancer Chemotherapy and Pharmacology (3)
  4. Cancer Research (3)
  5. Cancer (2)
  6. JAMA - Journal of the American Medical Association (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (29)
  2. American Association for Cancer Research (18)
  3. Springer (4)
  4. American Medical Association (2)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (68)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial
    Journal Article

    Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S. M.; Reed, D. R.; Okuno, S. H.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save
  • A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS)
    Meeting Abstract

    Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S.; Reed, D. R.; Okuno, S. H.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Meeting Abstract

    Postow, M. A.; Yuan, J.; Panageas, K.; Bogatch, K.; Callahan, M.; Cheng, M.; Schroeder, S. E. A.; Kendle, R. F.; Harding, J. J.; Dickson, M. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma
    Meeting Abstract

    Gounder, M. M.; Dickson, M. A.; Wu, N.; Ivy, S. P.; Carvajal, R. D.; D'Angelo, S. P.; Keohan, M. L.; Qin, L. X.; Erinjeri, J. P.; Takebe, N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M. A.; Keohan, M. L.; Tap, W. D.; Antonescu, C.; Landa, J.; Qin, L. X.; Dohrenwend, E. G.; Rathbone, D.; Ustoyev, Y.; Condy, M. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma
    Meeting Abstract

    Carvajal, R. D.; Ambrosini, G.; Wolchok, J. D.; Chapman, P. B.; Dickson, M. A.; D'Angelo, S. P.; Bluth, M. J.; Paucar, D.; Fusco, A.; Bohr, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A nonrandomized, phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma
    Journal Article

    Ang, C.; O'Reilly, E. M.; Carvajal, R. D.; Capanu, M.; Gonen, M.; Doyle, L.; Ghossein, R.; Schwartz, L.; Jacobs, G.; Ma, J.; more...
    Gastrointestinal Cancer Research (2012)

    Fulltext@MSK | Save
  • Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance
    Journal Article

    Ambrosini, G.; Pratilas, C. A.; Qin, L. X.; Tadi, M.; Surriga, O.; Carvajal, R. D.; Schwartz, G. K.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Uterine leiomyosarcomas are driven by cell cycle deregulation
    Meeting Abstract

    Barlin, J.; Leitao, M.; Qin, L.; Bisogna, M.; Olvera, N.; Shih, K.; Hensley, M.; Schwartz, G.; Boyd, J.; Levine, D.
    Gynecologic Oncology (2012)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST)
    Meeting Abstract

    D'Adamo, D. R.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C.; Qin, L.; Antonescu, C.; Lefkowitz, R. A.; Schwartz, G. K.; Maki, R. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save